ArticleMicrobial biotechnology2020
SEVA 3.1: enabling interoperability of DNA assembly among the SEVA, BioBricks and Type IIS restriction enzyme standards.
Article in Microbial biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 57 citations in OpenAlex.
- Applications of synthetic biology in biomedicine.Molecular biomedicine · 2026Review
- Engineering rhizobacterial communities for soil and plant health.Microbiology (Reading, England) · 2026Review
- Rhodo-Box: A Synthetic Biology Toolbox to Facilitate Metabolic Engineering ofACS synthetic biology · 2026Article
- Going beyond size: exploring the metabolic burden inSynthetic biology (Oxford, England) · 2026Article
- MOSAIC: A Highly Efficient, One-Step Recombineering Approach to Plasmid Editing and Diversification.ACS synthetic biology · 2025Article
- Combinatorial engineering pinpoints shikimate pathway bottlenecks in para-aminobenzoic acid production in Pseudomonas putida.Journal of biological engineering · 2025Article
- Boosting Dibenzothiophene Biodesulfurization Through Implantation of a Refactored DBT Pathway in a Tailored Pseudomonas putida Chassis.Microbial biotechnology · 2025Article
- AFrontiers in systems biology · 2025Article
- Controlling the expression of heterologous genes in Bdellovibrio bacteriovorus using synthetic biology strategies.Microbial biotechnology · 2024Article
- GenoMine: a CRISPR-Cas9-based kill switch for biocontainment ofFrontiers in bioengineering and biotechnology · 2024Article
- Metagenomics harvested genus-specific single-stranded DNA-annealing proteins improve and expand recombineering in Pseudomonas species.Nucleic acids research · 2023Article
- Increasing cellular fitness and product yields in Pseudomonas putida through an engineered phosphoketolase shunt.Microbial cell factories · 2023Article
- SEVA 4.0: an update of the Standard European Vector Architecture database for advanced analysis and programming of bacterial phenotypes.Nucleic acids research · 2023Article
- Multilayered safety framework for living diagnostics in the colon.Frontiers in systems biology · 2023Article
- A User's Guide to Golden Gate Cloning Methods and Standards.ACS synthetic biology · 2022Review
- Phosphite synthetic auxotrophy as an effective biocontainment strategy for the industrial chassis Pseudomonas putida.Microbial cell factories · 2022Article
- Tools of the trade: plasmid repositories and standardized plasmid manipulation for molecular and synthetic biology.Microbial biotechnology · 2022Article
- SEVAtile: a standardised DNA assembly method optimised for Pseudomonas.Microbial biotechnology · 2022Article
- When metabolic prowess is too much of a good thing: how carbon catabolite repression and metabolic versatility impede production of esterified α,ω-diols in Pseudomonas putida KT2440.Biotechnology for biofuels · 2021Article
- ReScribe: An Unrestrained Tool Combining Multiplex Recombineering and Minimal-PAM ScCas9 for Genome RecodingACS synthetic biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robust synthetic biology applications rely heavily on the design and assembly of DNA parts with specific functionalities based on engineering principles. However, the assembly standards adopted by different communities vary considerably, thus limiting the interoperability of parts, vectors and methods. We hereby introduce the SEVA 3.1 platform consisting of the SEVA 3.1 vectors and the Golden Gate-based 'SevaBrick Assembly'. This platform enables the convergence of standard processes between the SEVA platform, the BioBricks and the Type IIs-mediated DNA assemblies to reduce complexity and optimize compatibility between parts and methods. It features a wide library of cloning vectors along with a core set of standard SevaBrick primers that allow multipart assembly and exchange of short functional genetic elements (promoters, RBSs) with minimal cloning and design effort. As proof of concept, we constructed, among others, multiple sfGFP expression vectors under the control of eight RBSs, eight promoters and four origins of replication as well as an inducible four-gene operon expressing the biosynthetic genes for the black pigment proviolacein. To demonstrate the interoperability of the SEVA 3.1 vectors, all constructs were characterized in both Pseudomonas putida and Escherichia coli. In summary, the SEVA 3.1 platform optimizes compatibility and modularity of inserts and backbones with a cost- and time-friendly DNA assembly method, substantially expanding the toolbox for successful synthetic biology applications in Gram-negative bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.